So-Young (SY) Q1 2026 Earnings Call Transcript

So-Young reported Q1 revenue of RMB 432.8 million, up 45.6% year over year, driven by aesthetic center revenue that surged 185.8% to RMB 282.4 million and represented over 65% of total sales. Gross margin in the aesthetic center business improved to 27%, but profitability remains negative, with net loss widening to RMB 49.2 million and non-GAAP net loss to RMB 46.6 million. Management guided Q2 aesthetic treatment service revenue to RMB 307 million-RMB 317 million, implying 112.6%-119.5% growth, while highlighting continued clinic expansion, physician growth, and new blockbuster products.

Analysis

SY is starting to look less like a consumer internet monetization story and more like an operator of a small-but-growing specialty care network. The key second-order effect is that clinics are now becoming the demand-generation engine for upstream products, which should improve gross mix if management can keep conversion high; that matters more than the top-line growth rate itself because it raises switching costs and weakens pure-channel competitors. The referral share is especially important: once customer acquisition becomes predominantly word-of-mouth, the model can sustain growth with lower marginal CAC, creating operating leverage that is not yet fully visible in the reported loss line.

The most important signal in the quarter is not revenue growth, but the widening gap between mature centers and ramp-up centers. That implies the business is crossing the hardest phase of the rollout curve: newer units are learning faster and reaching economic viability sooner, which should compress payback periods over the next 2-4 quarters if unit economics hold. The flip side is that the current cash burn is being masked by expansion accounting; if center openings accelerate faster than same-store maturation, the market may re-rate this as a capital-intensive rollout rather than a self-funding chain.

Consensus is likely underestimating how much of the upside is tied to China’s premiumization of light aesthetics rather than overall industry growth. The real competitive threat is not traditional clinics but other scaled operators that can replicate standardized physician-led consults and supply-chain integration; if that imitation emerges, SY's current differentiation could narrow quickly. Near term, the stock should trade on two catalysts: Q2 guidance execution and evidence that mature-center contribution is enough to offset higher S&M and G&A, because that is the threshold for the market to believe profitability is a 12-18 month issue rather than an indefinite one.

Key Decisions for Investors

• Long SY on a 3-6 month horizon, but only on pullbacks or after confirmation that Q2 aesthetic-treatment revenue lands in the guided range; upside is meaningful if the market starts valuing the chain economics rather than the current net loss.
• Pair trade: long SY / short a traditional offline beauty-services or fragmented clinic operator proxy in Asia, to express the view that standardized, physician-led networks win share as consumers become more value- and trust-sensitive.
• Buy SY call spreads 2-4 months out to capture potential re-rating from another clean guide-up; define risk tightly because the main failure mode is expansion outpacing monetization, not demand collapse.
• If SY rallies >15% on guidance alone, trim half and wait for proof that mature centers continue to expand per-unit revenue, since the stock is likely to overshoot before the market has evidence of sustainable profitability.
• Avoid outright shorting here; the better short is a basket of local competitors without upstream integration or referral flywheels, because SY’s moat is improving faster than headline losses suggest.